NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Clementia Pharmaceuticals Inc. (“Clementia” or the “Company”) (NASDAQGS: CMTA) stock prior to February 25, 2019.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Clementia to Ipsen for US$25 per share. In addition, shareholders will receive a Contingent Value Right of US$6.00 per share payable upon completion of certain benchmarks. To learn more about the action and your rights, go to:
https://www.zlk.com/mna/clementia-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Clementia merger investigation concerns whether the Board of Clementia breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Ipsen is underpaying for Clementia shares, thus unlawfully harming Clementia shareholders. Clementia’s largest shareholder, OrbiMed Private Investments IV, LP, has already agreed to tender its shares.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com